MoonLake Immunotherapeutics MLTX
Super Investor & Insider
Nessuna transazione insider negli ultimi 6 mesi.
Fondi: 13F-HR alla SEC. Insider: acquisti (P) e vendite (S) in borsa da SEC EDGAR, ultimi 12 mesi.
About
MoonLake Immunotherapeutics is a clinical-stage biopharmaceutical company dedicated to developing next-level therapies for serious inflammatory diseases. The company targets over-expression of interleukins IL-17A and IL-17F, which drive conditions such as psoriasis, hidradenitis suppurativa (HS), psoriatic arthritis (P…
SectorHealthcare
ExchangeNASDAQ
IndustryBiotechnology
CountrySwitzerland
Employees130
TickerMLTX
Statistics
Market Cap$1.38B
Revenue (TTM)—
Net Income-$227.3M
Net Margin—
EPS$-3.53
P/E-5.25
P/S—
P/B4.97
EV/EBITDA-3.90
ROE-77.8%
Dividend Yield—
Price$19.16
Data: Twelve Data · Revenue = mcap / P/S